Zydus Cadila gets USFDA tentative nod for Droxidopa Capsules
Ahemdabad: Drugmaker Zydus Cadila recently announced that the company has received tentative approval from the United States Food and Drug Administration (USFDA) to market Droxidopa Capsules, in the strengths of 100 mg, 200 mg, and 300 mg.
Droxidopa is used to treat symptoms of low blood pressure when standing, caused by a certain medical condition (neurogenic orthostatic hypotension-nOH). This medication can lessen symptoms of low blood pressure when standing (orthostatic hypotension), such as dizziness and lightheadedness.
The drug will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.
The group now has 290 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India. The company discovers, develops, manufactures and markets a broad range of healthcare therapies.
The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.
Read also: COVID Antibody: Zydus Cadila gets nod for ICMR-NIV developed ELISA kit
